Silence Therapeutics plc: basic earnings per share
Basic earnings per share for Silence Therapeutics plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Silence Therapeutics plc financial histories
What this measure means
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Reading these values
This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -0.63 | USD/shares | 2026-03-05 | 10-K · 0001193125-26-092591 |
| 2024-01-01 | 2024-12-31 | -0.33 | USD/shares | 2026-03-05 | 10-K · 0001193125-26-092591 |
| 2023-01-01 | 2023-12-31 | -0.49 | USD/shares | 2025-02-27 | 10-K · 0000950170-25-029129 |
| 2022-01-01 | 2022-12-31 | -0.52 | USD/shares | 2025-02-27 | 10-K · 0000950170-25-029129 |
Related financial histories
- Silence Therapeutics plc: total assets
- Silence Therapeutics plc: total liabilities
- Silence Therapeutics plc: stockholders equity
- Silence Therapeutics plc: cash and cash equivalents
- Silence Therapeutics plc: net income or loss
- Silence Therapeutics plc: operating cash flow
- Silence Therapeutics plc: capital expenditure payments
- Silence Therapeutics plc: contract revenue excluding tax
- Silence Therapeutics plc: financing cash flow
- Silence Therapeutics plc: investing cash flow
- Silence Therapeutics plc: retained earnings or deficit
- Silence Therapeutics plc: basic weighted-average shares
- Silence Therapeutics plc: diluted weighted-average shares
- Silence Therapeutics plc: diluted earnings per share
- Silence Therapeutics plc: income tax expense or benefit
- Silence Therapeutics plc: net property, plant and equipment
- Silence Therapeutics plc: share-based compensation expense
- Silence Therapeutics plc: operating income or loss
- Silence Therapeutics plc: current assets
- Silence Therapeutics plc: current liabilities
- Silence Therapeutics plc: goodwill carrying amount
- Silence Therapeutics plc: net current accounts receivable
- Silence Therapeutics plc: gross profit
- Silence Therapeutics plc: research and development expense
Inspect the source
- Entity
- Silence Therapeutics plc / CIK 0001479615
- Captured
- 2026-09-20T09:08:49.927Z
- SEC response SHA-256
53a41c2fc340f0957df27b9d6349ef48239d12832ee112be6b78554d763c1b78
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001479615.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))